Showing posts with label Sufferers. Show all posts
Showing posts with label Sufferers. Show all posts

Tuesday, August 22, 2017

How Friends And Family Can Help Pain Sufferers


Today's post from paincommunity.org (see link below) looks at another aspect of care-giving when it comes to people living with relentless pain. This time it gives tips for family and friends and presents them from the point of view of the sufferer him- or herself. Many people with chronic pain feel misunderstood, disbelieved, unappreciated, ignored even and this is a plea for a little more understanding from those around them. of course, nobody pretends that people in pain are easy to live with but sometimes family and friends are at a loss as to how to help. This article suggests a few ideas.






What Can I Do? Tips for the Families and Friends
Posted by Janice Reynolds | January 14, 2014

The presence of persistent (aka chronic) pain is often “the elephant in the room”. For those of us who have persistent pain, daily living can be a challenge. Though we may not “look” like there is a problem, there is. For some, our pain is well controlled and for others it isn’t. For all of us, pain dictates how we spend our day as well as how we do things. It is very fatiguing even at the best. These are some thoughts and suggestions I wish to pass on to our family and friends. This is a response to the well-meaning comment: “What can I do?” This simple question can be overwhelming.

Tips That Can Make a Difference:

 
1. Don’t avoid me. Be the friend or loved one you have always been. Please visit. Find out or call first to be sure it is a good time for company.


2. Let’s talk together about it. Try not offer advice unless asked. You might start off by asking if I feel like talking about it at that moment or later.


3. Pain isolates; cry with me; laugh with me; let me know my feelings and needs are all right. Be patient and caring. Acknowledge my pain. Validate my feelings good and bad; loss, hope, sadness, anger, acceptance.


4. Remember persistent pain doesn’t mean the same level of pain is present all the time. Even if I have a good pain plan there are times my pain can elevate and spiral out of control. If you notice non-verbal cues, like a change in my mood, becoming very still or more restless or the inability to tolerate noise or light, encourage me to use the familiar techniques I depend on to lessen my pain; this could include taking recommended medications.


5. Don’t be afraid to touch me. Ask first if you have doubts; holding my hand lightly may be okay where squeezing it isn’t.


6. Learn the difference between physical dependence and addiction; I may depend on pain medication but may not have a problem with the misuse or abuse if it. These are very different situations.


7. If there is something you don’t understand, let me know so I can better explain it. Never be judgmental. Do not be afraid to be honest with me either.


8. Help me make a grocery list, if needed. Either offer to go with me or even shop for me.


9. Offer to watch my children or pay for a reliable babysitter for a while so I can have a little alone time with my spouse or by myself. They can probably use a break from me as well.


10. Cook or bring over a meal on occasion. Preparing something for the freezer for a time when I am having a bad day would be a life saver.


11. If you find I have fallen behind with cleaning, gently offer to help—dust, vacuum, wash dishes or clothes.

I know there are others. What would help you the most? Please pass this along to the families and friends of people you know who live with pain (including yourself); maybe we will get the elephant out of the room or at least halfway out the door.

http://paincommunity.org/what-can-i-do-tips-for-the-families-and-friends/

Friday, August 18, 2017

Anti Opioid Measures Affect Genuine Pain Sufferers


Today's post from the always excellent pain-topics.org (see link below) talks about the current political hysteria concerning opioids and opioid abuse across the world. True there are recreational users who abuse both the drugs and the system but there are also so many neuropathy and other non-cancer pain sufferers who depend on these drugs to get by each day. Authorities in many lands are introducing stringent measures to control opioid abuse but innocent people are being caught up in the backlash and being denied the drugs they need and deserve. You can almost understand the motives behind this when talking about drug abuse but if the reason also involves money, as is suggested here in Australia, then it is clearly unacceptable to chronic pain sufferers. A very interesting article.


Opiophobia Alive & Well in Oz
Posted by SB. Leavitt, MA, PhD Thursday, January 24, 2013

With all the recent ruckus over prescription opioids and sensational news headlines in the American press inciting fears of these medications, it is easy to believe that the United States is the only country facing such challenges. Apparently, the news is even worse from “down under” in Australia.

According to a brief news item — by Renee Viellaris and appearing in The Australian on January 19, 2013 [here] — physicians will “begin weaning some patients off pain medication as the nation's insatiable habit of pill popping has left health and law enforcement agencies buckling under pressure.” New pharmaceutical guidelines, to be presented this year to state and federal health ministers, will disallow prescribing some patients with “highly addictive and popular pain pills.”

The news report claims that the move has been prompted by the financial drain on the federally-funded Pharmaceutical Benefits Scheme (PBS) from excessive analgesic prescribing, misuse of the medicines, and “research showing long-term use of opioids is counterproductive.” Based on 2010 figures from the Australian National Centre for Education and Training on Addiction (NCETA), in that single year demand for subsidized prescriptions for two types of popular analgesics — oxycodone and fentanyl — cost taxpayers an extra $18 million [$18.9 million USD].

Dr. Steve Hambleton, federal president of the Australian Medical Association, confirmed that “some patients with noncancer pain would have to be weaned off the drugs because they were too expensive and were no longer clinically appropriate. Patients with long-term back or hip pain and those with sporting injuries who take the popular drugs face being directed to alternative therapies, including yoga.”

Hambleton called for more money from government to set up chronic pain clinics in hospitals, but conceded that the new regulations will dramatically change how pain is treated, and at a time when policy makers are also coping with an ageing population. “Some patients will have to be weaned off (and will have to do) things like physical therapy and focus on what you can do and not what you can't — more of a positive attitude,” he said in the news article.

The news report concludes that, “Research provided by NCETA shows that the per capita amount of morphine-equivalent drugs Australians are taking has exploded in the past 30 years.” Furthermore, “the number of Queenslanders on opioid dependence programs is dramatically increasing.”

COMMENTARY: The news report, brief as it is, tells a grim story of what may lie ahead for patients with chronic pain in Oz. And, unfortunately, this is not unlike what is occurring or may happen in other parts of the world, including the U.S.

Our quick scan of the websites of Australian organizations — Chronic Pain Australia serving patients/advocates, and the Australian Pain Society serving healthcare professionals — found no mention of these dire developments. Among other concerns, it would be interesting to know of what research evidence authorities are examining that proves the long-term use of opioid analgesics is “counterproductive.”

The news article notes that the number of persons in Queensland entering opioid-dependence treatment programs has been “dramatically increasing.” However, an accompanying chart shows the rise was only 19% — from roughly 4,900 to 5,800 persons — during the 5-year span 2008 to 2012. It does not say what proportion was attributable to prescription opioid abuse/addiction, or whether this was actually a favorable trend suggesting that more persons with substance-use problems are seeking and getting much needed care. [The U.S. CDC had presented some time ago similarly puzzling data on treatment-program admissions, discussed in an UPDATE here.]

Saving money on federally-funded prescription plans may seem like a worthwhile goal, but we wonder if authorities have considered the unintended consequences — financial and otherwise — of leaving large populations adrift to suffer chronic pain. It seems rather cavalier to suggest that these patients should adopt more positive attitudes and participate in alternative therapies, like yoga, since such interventions only work if they can get out of bed and move nimbly about without adequate pain-relieving medication.

http://updates.pain-topics.org/2013/01/opiophobia-alive-well-in-oz.html

Friday, August 11, 2017

Alpha Lipoic Acids Potential For Neuropathy Sufferers


Today's post from podiatrytoday.com (see link below) takes another, more in-depth look at the positive effects of Alpha Lipoic Acid supplements for people living with neuropathy (not just diabetics, as the title suggests). If you use the search button to the right of this blog, you will find many more articles about alpha lipoic acid, often in conjunction with another co-enzyme...Acetyl l-Carnitine. However, most of them just recommend these as supplements for neuropathy sufferers, without really telling us why. This article goes into much more detail regarding research and as such is definitely worth a read. Three points to remember here: 1) not everybody responds to alpha lipoic acid, 2) you need fairly high doses (up to 600mg per day) and 3) although the article suggests it's inexpensive, it can be quite pricey for the higher doses.
 

The Emerging Role Of Alpha-Lipoic Acid For Diabetic Neuropathy
Monday, 06/22/15 | Issue Number: Volume 28 - Issue 7 - July 2015
Author(s): Kevin Ragothaman, BS, and David Shofler, DPM, MSHS



Neuropathy is a common and well-known complication of chronic hyperglycemia due to diabetes mellitus. Distal symmetric polyneuropathy, a form frequently affecting patients with diabetes, characteristically begins in the toes and traverses proximally in symmetric fashion.

Symptoms of this late complication include loss of sensation, vibration sense, temperature sensation and muscle weakness. Often, these patients will describe hot, burning, tingling or throbbing pain that accompanies these symptoms. Those with distal symmetric polyneuropathy also have nighttime pain, which imposes a substantially detrimental effect on their quality of life.1 Researchers have also found increasing age, obesity and peripheral arterial disease to be risk factors for the eventual development of neuropathy.2

There are several strategies for alleviating neuropathic pain. Current mainstays include providing symptomatic treatment with anticonvulsants, such as pregabalin (Lyrica, Pfizer) and gabapentin (Neurontin, Pfizer), or tricyclic antidepressants. However, these medications merely relieve the symptoms and do not alter the actual pathogenetic mechanism of the disease. Furthermore, these medications are associated with adverse effects and contraindications that limit the utility of these drugs.3 Medications that modify disease progression by addressing the underlying cause of symptoms would be useful in providing long-term care for our patients, ideally without side effects.

Oxidative stress and free radical generation are deeply implicated in the development of late diabetic complications. Host antioxidant defenses act to reduce reactive oxygen species that oxidative phosphorylation in the mitochondria normally produce. Excessive glucose metabolism increases production of these free radicals and persistently high blood glucose causes the body to take up glucose through other pathways that increase free radical formation.

These processes are known to facilitate increased production of acetylated glycation end products (AGEs), protein kinase C and nitric oxide intermediates, which research has linked with microvascular and macrovascular complications involved with nerve degeneration.4 The harmful effects of AGEs occur through intracellular damage and interaction with their receptor for advanced glycation endproducts (RAGE). This leads to expression of nuclear factor kappa B (NF-KB) and consequent production of cytokines and procoagulant factors.5 In fact, authors have specifically shown that AGEs alter structural proteins of peripheral nerve tissue, namely by glycosylation of myelin protein in Schwann cells and modification of its basement membrane proteins.6

Given the influence of chronic hyperglycemia on complications of diabetes, controlling blood sugar levels in patients though lifestyle modification and dietary restriction is essential. However, this principle can be difficult for many patients to attain. Lowering blood sugar may not significantly improve the symptoms of clinical neuropathy in all patients with diabetes and one also needs to consider the occurrence of hypoglycemic episodes with enhanced glucose control for patient safety.7


A Closer Look At The Research On Alpha-Lipoic Acid

 
When approved therapeutic options fail to alleviate the pain associated with peripheral neuropathy, doctors should consider the use of antioxidants as a supplement. Alpha-lipoic acid is one such endogenously produced molecule that researchers have shown to be a scavenger of certain free radicals and a recycler of other antioxidants.8 The antioxidant properties of this inexpensive over-the-counter medication make it a potential candidate for correcting the underlying pathogenesis of diabetic complications.

Various researchers have studied the clinical use of alpha-lipoic acid for diabetic complications and it has been associated with limited side effects. A meta-analysis conducted in Germany including 1,258 patients analyzed multiple clinical trials that investigated the use of alpha-lipoic acid for distal symmetric polyneuropathy.9 Using intravenous infusion of 600 mg per day for three weeks, Ziegler and colleagues demonstrated improvements in pain and paresthesia as per the Total Symptom Score and improved pinprick sensation, touch pressure sensation and ankle reflexes as per Neuropathy Impairment Scores.10 The authors then evaluated the efficacy and dose-response effects of oral alpha-lipoic acid by using dosages of 600 mg, 1,200 mg and 1,800 mg among three groups for five weeks. They noted a decrease in scores for stabbing and burning pain in all treatment groups, and concluded that the improvement of symptoms was not dose-dependent. Recorded adverse effects, the most common of which was nausea, were dose-dependent.

Ziegler and colleagues expanded upon these short-term findings by orally administering alpha-lipoic acid 600 mg once daily to patients with type 1 and type 2 diabetes with distal symmetric polyneuropathy.11 The authors extended the study timeline to four years, making it the longest randomized study of distal symmetric polyneuropathy to date. They found an improvement in certain neuropathic measurements, such as the pinprick test and muscular strength. However, their primary outcome composite score, which mainly included neurophysiologic nerve conduction studies, did not show significant improvement. The authors attributed this to the disease condition being unexpectedly static in the placebo group over the treatment period.

Despite this shortcoming, the authors found that administration of alpha-lipoic acid ameliorated many of the clinical symptoms of distal symmetric polyneuropathy, suggesting an improvement in microvascular blood flow to nerves mediated by the antioxidant effects of the drug.11 This series of work demonstrated promising results in supporting the use of once daily 600 mg of alpha-lipoic acid orally in alleviating symptoms associated with peripheral neuropathy in patients with both type 1 and 2 diabetes with no serious adverse events.

Authors have specifically investigated the influence of blood glucose on the efficacy of alpha-lipoic acid. While the aforementioned studies excluded patients with HbA1c greater than 10%, recent studies have aimed to reveal the effects of alpha-lipoic acid on those with and without good glycemic control. Ibrahimpasic administered 600 mg IV of alpha-lipoic acid for three weeks and followed this with 600 mg oral for four months.12 The patients had concomitant treatment with insulin and oral anti-diabetes drugs. In regard to the 20 patients with type 2 diabetes in the study, there were two groups: those with HbA1c less than 7% (group one) and those with HbA1c greater than 7% (group two). Both groups reported improvements in their subjective opinion of their condition.

However, Ibrahimpasic found that group one had significant improvement in paresthesia, night leg pain and gait disturbance, suggesting that alpha-lipoic acid treats symptoms of distal symmetric polyneuropathy more effectively when clinicians pair this with better glucose control of the patient with diabetes.12

What You Should Know About The Specific Effects Of Alpha-Lipoic Acid

 
Numerous studies have gauged the effect of alpha-lipoic acid on other major factors associated with diabetes, including insulin sensitivity and obesity.13,14 Lee and colleagues showed the influence of antioxidants on insulin sensitivity by demonstrating increased glucose uptake in skeletal muscles treated with alpha-lipoic acid.15 In addition, they found that triglyceride content was lower in soleus muscles.
Recent work using high-fat fed obese Zucker rats with a genetic and dietary predilection for obesity and dyslipidemia demonstrated that alpha-lipoic acid provides protection against triglyceride accumulation in the liver.16 A Chinese study involving obese patients with impaired glucose tolerance, putting them at high risk for type 2 diabetes, revealed improved insulin sensitivity and plasma lipid profile with only a two-week regimen of 600 mg alpha-lipoic acid daily.17

Further, an Italian study observed significant decreases in weight, body mass index, blood pressure and abdominal circumference in both pre-obese and obese patients treated with 800 mg alpha-lipoic acid daily for four months.18 Although it is difficult to attain normoglycemia in patients with developed diabetes, an Indian study demonstrated the ability of a variety of antioxidants to decrease HbA1c levels in people with type 2 diabetes after 90 days of administration.19 Patients who received alpha-lipoic acid showed a significant decrease in mean HbA1c from 11.49 to 9.96 percent.

Alpha-lipoic acid has also shown protective effects on the kidneys as demonstrated by a decrease in microalbuminuria in type 2 patients with diabetes after treatment with 600 mg daily alpha-lipoic acid for six months.20 Morcos and colleagues also looked at the beneficial effect of alpha-lipoic acid on endothelial cells in patients with type 1 and 2 diabetes, using an increase in unbound plasma thrombomodulin as a marker of endothelial cell damage. Patients treated with daily dosing of 600 mg alpha-lipoic acid had a significant decrease in plasma thrombomodulin after 18 months.21 It is also noteworthy that patients with renal impairment taking alpha-lipoic acid do not require dose adjustment.22

The observed side effects of alpha-lipoic acid have been minimal although Ziegler and coworkers noted nausea, vomiting and vertigo from oral administration.9 Of these side effects, nausea was most common, affecting 13 percent of the group receiving the oral 600 mg daily dosage of alpha-lipoic acid with vertigo affecting 4 percent and vomiting affecting 2 percent of the same group. Recent studies have also reported rare incidents of insulin autoimmune syndrome, characterized by hypoglycemia and high serum insulin levels in genetically predisposed Caucasian and Japanese patients taking alpha-lipoic acid.23

In Conclusion

 
The antioxidant properties of alpha-lipoic acid have long been known and the potential benefit of the modality in a wide array of diabetic complications is clear. Despite the positive results researchers have observed with alpha-lipoic acid’s effect on the symptoms of diabetic peripheral neuropathy, robust evidence showcasing its ability to reverse progression of complications is not yet available. More long-term studies may help gauge the efficacy of the drug, possibly as a supplement to anti-diabetes medication.

Lifestyle modification is another critical factor that patients cannot ignore. Many foods such as broccoli and spinach contain small amounts of alpha-lipoic acid and other antioxidants that patients can easily add to a daily diet. We advise regular monitoring for patients taking 600 mg oral alpha-lipoic acid daily and one should responsibly document their condition. Observe patients for side effects, including episodes of hypoglycemia. Patients should maintain vigilant blood sugar control. With these cautions in mind, alpha-lipoic acid can be a very useful and safe option in the management of diabetic peripheral neuropathy.

Mr. Ragothaman is a third-year student at the Western University of Health Sciences College of Podiatric Medicine.

Dr. Shofler is an Assistant Professor at the Western University of Health Sciences College of Podiatric Medicine.

References
Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47(2):123-8.
Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic Pain in Diabetes, Prediabetes and Normal Glucose Tolerance: The MONICA/KORA Augsburg Surveys S2 and S3. Pain Medicine. Pain Med. 2009 Mar;10(2):393-400.
Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008;24 (Suppl 1):S52-7.
Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005;4(1):5.
Mohamed AK, Bierhaus A, Schiekofer S, et al. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors. 1999;10(2-3):157-67.
Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann NY Acad Sci. 2005;1043:598e604.
Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012, Issue 6. Art. No.: CD007543.
Packer L, Witt E, and Tritschler HJ. Alpha-Lipoic Acid as a Biological Antioxidant. Free Radical Biology Medicine. 1995;19(2):227-250.
Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70.
Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114-21.
Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054-60.
Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arch. 2013;67(1):7-9.
Gavin TP, Ernst JM, Caudill SE, et al. Insulin sensitivity is related to glycemic control in type 2 diabetes and diabetes remission after Roux-en Y gastric bypass. Surgery. 2014;155(6):1036-43.
Chaturvedi N. The burden of diabetes andits complications: trends and implications forintervention. Diabetes Res Clin Pract. 2007;76 Suppl 1:S3-12.
Lee WJ, Song KH, Koh EH, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332(3):885-91.
Carrier B, Wen S, Zigouras S, et al. Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS One. 2014;9(3):e90863.
Zhang Y, Han P, Wu N, et al. Amelioration of lipid abnormalities by alpha-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring). 2011 Aug;19(8):1647-53.
Carbonelli MG, Di Renzo L, Bigioni M, et al. Alpha-lipoic acid supplementation: a tool for obesity therapy? Curr Pharm Des. 2010;16(7):840-6.
Udupa A, Nahar P, Shah S, et al. A comparative study of effects of omega-3 fatty acids, alpha lipoic acid and vitamin E in type 2 diabetes mellitus. Ann Med Health Sci Res. 2013;3(3):442-6.
Bao XH, Xu J, Chen Y, et al. Alleviation of podocyte injury: the possible pathway implicated in anti-inflammation of alpha-lipoic acid in type 2 diabetics. Aging Clin Exp Res. 2014; 26(5):483-9.
Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract. 2001;52(3):175-83.
Teichert J, Tuemmers T, Achenbach H, et al. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol. 2005;45(3):313-28.
Gullo D, Evans JL, Sortino G, et al. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking alpha-lipoic acid. Clin Endocrinol (Oxf). 2013; 81(2):204-9.

For further reading, see the DPM Blog “Exploring The Potential Of Alpha Lipoic Acid For Diabetic Neuropathy” by Allen Jacobs, DPM at http://tinyurl.com/9whjlyo .

http://www.podiatrytoday.com/emerging-role-alpha-lipoic-acid-diabetic-neuropathy

Sunday, July 23, 2017

The Opioid Row Is Directly Relevant To All Neuropathy Sufferers


Today's post from startribune.com (see link below) is of interest to all neuropathy patients, even if you are only taking paracetamol to reduce your symptoms. It addresses the so-called opioid addiction problem but remember, once you begin serious treatment for your neuropathic pain, you're taking drugs meant for other conditions and they all have potential side effects and potential addiction problems. Most people start for instance, with Amitriptyline (which seldom works when neuropathy takes hold but even this is an antidepressant and can have adverse effects on your health. From that point on, the drugs just get stronger, until after you've exhausted them all, you end up on opioid family medications and remember...this is just to control the pain...it does nothing to help the nerve damage itself. So yes, this article applies directly to you and is worth taking sides on. The point of the article is that although politicians claim this is an 'addiction and criminality' problem, it's not, it's a chronic pain problem for which those drugs are ultimately the only solution. Therefore the article quite rightly aims for a course of treatment that is multi-disciplinary and includes drugs but also many other ways to tackle chronic pain. If you scan down the title list to the right of this blog, you will find many articles relating to non-drug treatments to help you live with chronic pain - they need to be included in any doctor's approach to chronic pain. so that you don't just walk away with a prescription for hard drugs in your hand but have a list of other tools which will reduce the need for those drugs and help cope with chronic pain as well. However, don't be fooled...the drugs are necessary; the pain is real and you're not a junkie for needing them. It's just that you can help yourself in other ways too. Worth a read.


Drop old doctor-centered model for a proactive, self-care approach. 
By James Fricton, Alfred Clavel and Mark Weisberg
April 15, 2016

 
Health care and addiction: Instead of opioids, prevent chronic pain


The effort announced by the Obama administration to address the growing opioid abuse problem misses the mark on why people become addicted to opioids. The real reason for the increase in opioid use is not about addiction, but rather about chronic pain.

Thus, the March 27 front-page article (“Taming the pain without the pills”) on an innovative approach to help opioid-addicted patients with chronic pain is important and timely.

While major efforts are underway to prevent most other major health conditions, preventing chronic pain remains an enigma, overlooked by the public, neglected by the health care system and generally ignored by the scientific community. Chronic pain is the “elephant in the room” of health care, and we need to prevent it.

The Institute of Medicine (2011) and the National Pain Strategy (2016) state that chronic pain conditions are the No. 1 reason for the use of opioids, the No. 1 reason for seeking care, the No. 1 cause of disability and the No. 1 driver of health care costs — costing more than cancer, heart disease and diabetes. It costs the United States alone over $700 billion in health care and lost work. This is equivalent to 25 percent of total health care costs and nearly 5 percent of the U.S. total gross national product.

The personal impact in terms of suffering, loss of function, disability, depression, addiction, overdoses and more is incalculable.

The Obama administration strategy suggests that we need to wean thousands of people off these powerfully addictive substances or avoid distributing them in the first place. However, this assumes that people are taking them for nonmedical reasons. In the vast majority of cases, people have been prescribed opioid medications to manage chronic pain.

If we want to reduce opioid addiction and overdoses, we must focus more effort on preventing chronic pain without opioids. Pain conditions in the back, neck, head, face and other areas are caused by physical disorders of the muscles, joints, nerves and other tissues that may begin with an injury or strain and that then may persist due to the lifestyle risk factors that increase sensitization of the nervous system. Repetitive strain, poor sleep, stress, maladaptive postures, emotional problems and other factors can delay recovery. The majority of those with pain over one month in duration still have pain years later despite the use of opioids, pharmaceuticals, implanted devices, surgeries and other innovative treatments.

It’s time we shift the focus to preventing chronic pain. We spend billions on advances in pharmaceuticals, devices, surgeries and other innovative treatments for chronic pain, yet we fail to deliver long-term relief, primarily due to the lack of educating patients in self-management strategies to reduce these risk factors and enhance protective factors.

The Institute of Medicine states that the primary role of the health professional in caring for chronic pain requires guiding, coaching and assisting patients with day-to-day self-management, in addition to evidence-based medical treatments. However, most health professionals lack the time to perform this role and find little support and reimbursement for doing so. They rely on the patient to do so, but this often does not get done. The opioid epidemic is just one of many consequences.

We need to change our health care system. Solving the chronic pain problem requires changing our health care model from a passive model of doctor-centered care to a patient-centered transformative care model. Transformative care brings together evidence-based treatments with self-management training to reduce risk factors and enhance protective factors in each aspect of a person’s life. It helps people shift the balance from illness to health. Embracing patient-centered health care paradigms such as self-responsibility, education, personal motivation, social support, strong provider-patient relationships and long-term change are the key.

We also need to train health professionals and patients on how to prevent chronic pain and opioid addiction. One innovative example of this is the massive open online course (MOOC) titled “Preventing Chronic Pain: A Human Systems Approach” (www.coursera.org/course/chronicpain). This course provides free online education to help those who want to prevent chronic pain and opioid addiction. Course evaluations found 93 percent believed that the course made a difference in their lives and that 85 percent of health providers believe that it made a difference in their patient care. As one participant stated, “Absolutely fascinating and enlightening. This information should be part of every health care educational program!”

Patients and health care professionals can shift the balance from a passive, dependent role to one of being empowered, engaged and well-trained to not only prevent their chronic pain, addiction and disability but also to enhance health and well-being. Ultimately, this will best prevent the opioid problem, improve the quality of health care and significantly reduce health care costs. The “elephant in the room” will finally get addressed. Why not support this?

Dr. James Fricton is a professor and specialist with the HealthPartners Institute for Education and Research, the Minnesota Head and Neck Pain Clinic and the University of Minnesota. Dr. Alfred Clavel is a neurologist with the Minnesota Head and Neck Pain Clinic and department chair in pain management at HealthPartners. Dr. Mark Weisberg is a clinical psychologist with the Minnesota Head and Neck Pain Clinic and the University of Minnesota.

http://www.startribune.com/health-care-and-addiction-x2009-x2009-instead-of-opioids-prevent-chronic-pain/375905321/

Friday, July 7, 2017

Will a Better Attitude Towards Opioids Help Neuropathy Sufferers


Today's article from an unknown author writing for opioids.co.uk (see link below)is not an easy read but one that definitely stimulates discussion. The writer is clearly someone with a deep scientific knowledge of how opioids work and his or her political agenda aside, he makes a powerful case for a more open-minded approach to using opiods in the treatment of pain. It's not as if it's a new drug source; it's been used for thousands of years but it is a controversial one because of the perceived dangers of addiction and substance abuse. Much like marijuana, the authorities both political and medical, seem to see it always as a potential threat to society, rather than an effective weapon in the fight to control severe pain. Of course, as many of you know, it's already widely used in the treatment of neuropathic symptoms but almost always as a last-resort measure, when all else has failed.
This article tries to show that opioids are not something to be feared but an age old pain suppressor that deserves much better research, so that it may be possible to use it at an earlier stage. After all, the anti-depressants and anti-convulsants which are generally prescribed first, are not without unpleasant side effects of their own and are very often ineffective. However, it's a real hot potato as far as the FDA in the States and most governments across the world are concerned. They seem to have a vision based in the 19th century of half the population living in a drug-induced stupor. Time to trust the people a little more maybe?




FUTURE OPIOIDS

THE BIRTH OF A NEW GENERATION

A significant minority of the population only feel truly well on opioids. In effect, they self-medicate, taking responsibility for their own mental health in defiance of medical orthodoxy.

It would indeed be extraordinary if - alone among the neurotransmitter systems of the brain - the endogenous opioid families were immune from dysfunction. Enkephalins are critical to "basal hedonic tone" i.e. whether we naturally feel happy or sad. Yet the therapeutic implications of a recognition that dysfunctional endogenous opioid systems underlie a spectrum of anxiety-disorders and depression are too radical - at present - for the medical establishment to contemplate. In consequence, the use of opioid-based pharmacotherapies for "psychological" pain is officially taboo. The unique efficacy of opioids in banishing mental distress is neglected. Their unrivalled efficacy in treating "physical" nociceptive pain is grudgingly accepted.

Later this century and beyond, however, the development of highly selective, site-specific designer drugs and innovative gene-therapies may enhance our native opioid function and revolutionise mental health. Therapeutic intervention targeted on the opioid pathways will potentially enrich the quality of life of even the nominally "well", not least because - by the more enlightened health standards of posterity - we may all be reckoned mentally ill.

Today, by contrast, immense energy is devoted by the authorities into persecuting "illicit" narcotic users. Many drug-"abusers" feel well thanks only to the "non-therapeutic" use of opioids. They are stigmatised, pilloried and criminalised in a futile War Against Drugs. In the "Inquisition against pleasure", victims of medically-sanctioned human-rights abuses - e.g. the hundreds of thousands of drug "offenders" incarcerated in the Amerikan gulag - are officially supposed to believe their malaise-ridden drug-naïve states were "normal", "natural" and mentally healthy. In the course of our ill-conceived Drug War, vast resources are dissipated by the state-apparatus in an effort to choke off narcotic production and supply. When these efforts are temporarily successful, drug-deprivation makes the habitual opioid user feel ill; [s]he "cold-turkeys" with characteristic irritability, anhedonia, depression, sickness behaviour and sometimes raw physical pain. The ill-effects felt from involuntary deprivation of opioids are taken to demonstrate the likely ill-effects of legalised access, a paradox that might be thought laboured were its human costs not so tragic.

When caught up in the criminal justice system, users may be pressured into taking opioid antagonists like naltrexone (Trexan). Such drugs can induce dysphoria and suicidal despair. At best, their use subtly diminishes the victim's capacity ever to feel well. Meanwhile Chinese military surgeons have developed (2003) a new treatment weapon against narcotic users: surgical destruction of the pleasure centres. Western doctors are said to be following these procedures with interest, but are more likely to achieve their functional equivalent by non-surgical means.

Even where it is acknowledged that many opioid users have a pre-existing anxiety or depressive disorder in urgent need of relief, those so afflicted are fobbed off with often third-rate psychotropics instead. For a start, the monoamine hypothesis of depression - and the new classes of drug it has spawned (SSRIs, NARIs, SNRIs, NaSSAs, RIMAs etc to complement the dirty old tricyclics and irreversible unselective MAOIs) - is radically incomplete. A minority of people, admittedly, find such drugs effective. Often taking a licensed antidepressant is better than nothing at all - perhaps in part because of their positive effects on endogenous opioid peptide release. Yet even in the context of controlled clinical trials with relatively high dosage-regimens and artificially good rates of patient-compliance, it's rare for response-rates to reach more than 70%. Rates of full remission of depressive symptoms are far lower, perhaps 25-30%. Out "in the field", the picture is worse still. Adverse side-effects are common. Response may take weeks. Withdrawal reactions can be unpleasant.

A recognition of the crucial role of dopamine, and selective dopamine reuptake blockers, in sub-types of depressive mood-disorders might push response and remission rates higher. The mesolimbic dopamine system is critical to vitality, motivation, libido and a capacity to anticipate reward. Dopaminergics can also act as analgesics. They can also reverse the apathetic sedation induced by some antidepressants and opioid agonists. Yet the FDA stymies the licensing of effective dopamine reuptake-blocking mood-brighteners at home; and applies pressure to deny access to them abroad. This is because of worries about their (sometimes) faster efficacy - and mild psychostimulant effect - raise the spectre of "abuse-potential"; and proscription, persecution and indiction are favoured over consumer education. For Big Brother knows best.

More controversially, adding customised opioids, enkephalinase-inhibitors and kappa-antagonists to our therapeutic armamentarium may prove critical to boosting response- and remission-rates towards 100% in the decades ahead. Crudely, whereas dopamine mediates "wanting", mu opioid agonists mediate "liking". Both systems can be fruitfully enhanced. Depressive and dysthymic people often suffer from a dysfunctional opioid system and anhedonia - an incapacity to experience pleasure. Sometimes orthodox "antidepressants" may even make them feel worse. Yet controlled clinical trials of designer narcotics for refractory and/or melancholic depression, let alone their use by "normal" people with "ordinary" mood-disorders, are not imminent.

So what is to be done? Even in the context of today's crude agents, would some of us be better off as legalised junkies?

No, usually not, at least in contemporary society. Self-medicating users with enough resources to maintain a regular supply may indeed find they can function as well as, or better than, their drug-naïve state. Popular mythology aside, users don't seek to escalate dosage indefinitely: both humans and laboratory monkeys with unlimited access tend slowly to increase injection-frequency until eventually they self-administer a stable and subjectively optimal amount of the drug. Most users take heroin, not primarily to stave off the abstinence syndrome, but because they find life on heroin better than their pain-ridden life without it. Yet the existence of a typical heroin addict in prohibitionist society can still be exceedingly unpleasant at times. Contemporary opioid drugs, natural and synthetic alike, are flawed. The problem is not the euphoric well-being they can induce - an ill-named "adverse side-effect" - but their tendency to induce a financially ruinous tolerance; perhaps insidiously to dull the intellect; trigger nausea; slow digestive processes; and sometimes induce a parodoxical hyperalgesia. Most seriously, when taken in acute excess, today's opioids can cause respiratory depression. This is a consequence of their stimulation of the mu-2 receptors in the medullary respiratory centres of the brain. These problems are exacerbated a thousandfold, however, by the illegal status of narcotics in contemporary society. Dosage, purity and regularity of supply cannot be guaranteed; prices are inflated; quality-control is negligible; good hygiene is difficult. Pharmacological education is non-existent, whereas it ought to be part of the core curriculum. Opioid users are frequently forced into crime to pay for pharmacotherapies that should be cheaply and safely available; and damned for seeking a state of mind which will one day be their birthright: invincible happiness.

To promote emotional superhealth both durably and effectively, designer-opioids must be synthesised that are also subjectively nicer, richer and cleaner than today's product-line. For one of our three major endogenous opioid families is implicated in profoundly dysphoric psychological effects: a cruel negative-feedback system exists between the mu and kappa systems that "corrects" any "excess" tendency to well-being. Thus dynorphin activity at the kappa receptors tonically inhibits the release of dopamine from the mesolimbic terminals. By contrast, the mu-opioid receptor selective endomorphins, especially endomorphin 1, are potent antidepressants: they enhance mu opioid receptor-mediated dopamine release in the nucleus accumbens. If our well-being is to be sustainably enhanced, the balance between the two opposing opioid systems must be shifted.

The role of the mu receptors appears to be crucial in another respect. Today, people vary hugely in their sensitivity to pain. This sensitivity is genetically regulated. Pain perception - and, conversely, emotional well-being - is closely linked to the number of neuronal mu receptors. This number is controlled by a single gene, the mu opioid receptor gene. Pain-sensitivity is diminished when the receptors are present in relative abundance. When the receptors are reduced in number or missing altogether, relatively minor noxious stimuli may be perceived as painful.

In the short-to-medium term, then, we need better-targeted opioids, safer and more site-specific than the present crop. Smarter opioids can potentially be combined with cholecystokinin antagonists (e.g. proglumide); nitric oxide (NO) synthase inhibitors; peroxynitrite-blockers; and also, perhaps, better-designed NMDA receptor antagonists - co-analgesics with potential antidepressant efficacy that inhibit the onset of tolerance. Although mu receptor agonists are the best analgesics and euphoriants, selective delta receptor agonists and enkephalinase inhibitors may prove clinically valuable antidepressants. The development of centrally active and more selective kappa antagonists - which block the endogenous excess production and reuptake of dynorphin underlying many depressive and anxiety disorders - is also a priority. Orally active JDTic, a potent, exceedingly long-acting selective kappa antagonist, is currently undergoing preclinical testing. Kappa Therapeutics, the world's first conference dedicated to the kappa opioid receptor, was held in Seattle July 2011. In the meantime, Buprenorphine (Buprenex, Temgesic, Subutex), for instance, is certainly no panacea; but it would probably benefit a far wider section of the population than its current restriction to use in "detoxifying" heroin-addicts. Its role as a mixed mu agonist reduces buprenorphine's addictive potential as a euphoriant while increasing its safety in overdose. Buprenorphine's kappa receptor antagonism may contribute to its superior efficacy as an antidepressant. Even the humble codeine analogue tramadol (Ultram), a selective partial mu agonist analgesic with noradrenaline and serotonin reuptake inhibiting properties, can serve as a useful mood-brightening stopgap. Weak but non-negligible kappa agonism limits its therapeutic benefit. But contemporary medico-legal opiophobia ensures such usage remains strictly off-label.

THE QUEST FOR A DRUG-FREE SOCIETY

In the longer-run, however, irrespective of how clever our pharmacological interventions may one day be, we'd arguably be better off taking no drugs at all. For if there were nothing fundamentally wrong with our default-state of consciousness, then we wouldn't now try so hard to change it. Thus our sophisticated descendants may opt instead to rewrite the vertebrate genome and allow themselves life-long genetically pre-programmed bliss. They may "naturally" be animated by gradients of well-being beyond the bounds of normal human experience as an everyday part of mental health.

Wouldn't lifelong happiness make us stagnate? No. In our genetically-enhanced post-human successors, the functional analogues of aversive experience can potentially perform an analogous functional role to mental and physical pain in our Darwinian past, but without its textures of phenomenal nastiness. Our descendants' enriched dopamine function will enhance their drive, energy and will-power, not just hedonic capacity. Thus outright abolitionism is not technically infeasible - just ideologically problematic.

Tomorrow's bioscientists face another challenge. Taken in excess, opioid-based drugs of today tend to dull consciousness, inducing a dreamy warm contentment. The name "narcotic" derives from the Greek word for stupor. Indeed smacked-out bliss is typically used as the archetype of what any drug-or-gene-underwritten chemical utopia would be like. Most notably, soma in Aldous Huxley's Brave New World is depicted as a cross between a non-addictive opioid and a hangover-less tranquilliser. Thus Huxley's utopians enjoy only an empty imbecilic happiness, not life-enriching peak experiences. Unlike dopaminergics, soma doesn't increase incentive-motivation, nor does it heighten the felt intensity of experience. You can use soma to drift off to sleep.

Yet this negative stereotype of synthetic bliss is profoundly misleading. Addictive tranquillity is only one option among many. It reflects a poverty in our conception of the range of options for paradise-engineering that biotechnology puts on offer. In reality, the quality of our consciousness can be intensified, sharpened and radically diversified by creative psychopharmacology. Intellect and empathy, and not just mood, can be prodigiously enhanced when the ideology of Better Living Through Chemistry finally enters mainstream culture.

Better still, when a wholesale genomic rewrite - and not just piecemeal genetic tinkering - unfolds in the millennium ahead, then any chemical manipulation of our descendants' emotionally- and intellectually-enriched superminds may be redundant. At most, lifestyle drugs will offer an optional fine-tuning for the parameters of their well-being - set against a backdrop of native-born bliss. In the wake of any such Post-Darwinian Transition, a wide variety of social interactions will "naturally" trigger a far richer endogenous opioid release than occurs today; and do so from a much higher baseline of emotional well-being.

However, our present restrictive definitions of mental illness, and the technical challenges posed by large-scale genetic-rewrites, make germline gene-therapy seem a pipe-dream for now. In the present era, lifetime pure dysthymia afflicts far too many people; and periods of "mild" anxiety, malaise and depressive episodes blight the lives of hundreds of millions more. Meanwhile countless victims of chronic pain-disorders are condemned to a life of needless suffering by institutionalized opiophobia. Victims of the most unspeakable, spirit-crushing neuropathic or central pain are liable to be fobbed off with pain-management courses - "helping you to manage your pain" - rather than given the potent pain-relief they deserve. For with a bit of creative psychopharmacology, both the tolerance and adverse side-effects of chronic opioid use are manageable even with today's crude agents. Thanks to tomorrow's biotechnology, the real obstacles to curing the nasty side of life are set to become doctrinal, not technical. Suffering of any kind is due to become optional. It remains to be seen how quickly the ideological baggage of the past can be overcome.

http://opioids.co.uk/

Friday, June 23, 2017

Winter Warning For Neuropathy Sufferers


Today's post from seacoastonline.com (see link below) is especially relevant for our North American, European and Russian readers, who are experiencing a more extreme Winter than normal this year. Spring may be in the air for many of us (and Autumn in the southern hemisphere but much of the norther half of the world is still in Winter's icy grip. Bad news for neuropathy sufferers. This article (like so many) concentrates on diabetics with neuropathy but applies to us all and gives sound advice for those whose feelings in their feet and hands are strange, at best!
 

Severe winter puts stress on those living with diabetes
Posted Feb. 22, 2015

Manchester, NH — Individuals living with diabetes face increased risk in a severe winter because of cold, damp conditions and must take many precautions to avoid serious side effects.

“People with diabetes should avoid going out in severe cold,” said Cindy Kolenda, BS, CWCN, CFCN, a wound care specialist at Catholic Medical Center. “Their poor circulation can be worsened in cold temperatures, which increases the risk of frost bite.”

What makes cold temperatures even more risky is that some people with diabetes cannot feel their feet. Diabetic neuropathy is a type of nerve damage that can occur with diabetes. High blood sugar can damage nerves in the legs and feet. About 60 to 70 percent of people with diabetes have some form of neuropathy, according to the National Institutes of Health. Symptoms may occur at any time and intermittently.

“Diabetes works from your feet to your knees,” explained a 69-year old man participating in CMC’s Diabetes Self-Management Education (DSME) class. “It started as a tingling feeling in one foot then went to the other.” He likens it to the sensation of having a limb “fall asleep.” His doctor ordered tests for nerve damage. “You lie down and they stick needles from your knees to the bottom of your feet and toes. I had no feeling in the bottom of my feet. On the top of my toes, I felt a little bit there. ‘You have a case of neuropathy,’ I was told. ‘You may have a dead nerve and it won’t come back,’ they told me.”

Many people living with diabetes are vulnerable to foot problems. The American Diabetes Association estimates that one in five people with diabetes who seek hospital care do so for foot problems. Even small foot injuries can cause serious trouble. Poor foot care may lead to amputation of a foot or leg.

About 73,000 amputations were performed in people with diabetes in 2010 according to the American Diabetes Association. Diabetes can lead to peripheral arterial disease (PAD), which reduces blood flow to the feet. Reduced sensation from nerve disease is common. Together these problems can result in ulcers and infections that may lead to amputation.

“Avoid the cold and don’t let your feet get and stay wet,” said Kolenda. “Find boots that are a good fit and protective.” Footwear that is too loose or too tight can cause minor irritations like a blister that if not properly cared for may pose major risks. Diabetes treatment specialists also warn people about how to warm up their feet, indicating that hair dryers, fireplaces, and heating pads are unsafe. Without normal heat sensitivity, it is easy for someone to accidently burn themselves.

The layer between the shoe and your foot is important. Avoid socks with seams as they can cause rubbing and irritation. Do not wear socks that cut into your leg or ankle or that fall down and bunch up in your shoe. Choose a sock that is made of a breathable material, such as cotton, or a wicking material, such as microfiber, to keep bacteria from forming.

CMC cautions people to exercise proper foot care. Wash your feet every day. Dry them carefully, especially between the toes. Rub a thin coat of skin lotion over the tops and bottoms of your feet, but not between your toes. Wear shoes and socks at all times. Never walk barefoot. Always protect your feet by wearing shoes or hard-soled slippers or footwear.

People with diabetes should inspect their feet every day. “Look at your bare feet for red spots, cuts, swelling and blisters,” said Kolenda. “If you cannot see the bottoms of your feet, use a mirror or ask someone for help.” Kolenda said to call or see your health care provider if you notice cuts or breaks in the skin. Also, tell your health care provider if your foot changes color, shape, or just feels different (for example, becomes less sensitive or hurts).

http://www.seacoastonline.com/article/20150222/News/150229879

Thursday, June 1, 2017

Is Electroacupuncture Of Benefit To Neuropathy Sufferers


Today's post from updates.pain-topics.org (see link below) talks about electroacupuncture which is basically the application of needles that are connected to an electrical current, to acu-pressure points. It is aimed at relieving neuropathic pain. However, it's controversial to say the least, in that it has never been proved to relieve pain with any degree of effectiveness. Dr Leavitt looks at an Italian study of the effectiveness of electroacupuncture here but you may also have read about a new study regarding electroacupuncture now taking place in Korea (more info here). Acupuncture seems to be another therapy that works for some neuropathy patients and not others but in terms of relieving nerve pain (as opposed to muscular or joint pain) electro-acupuncture remains unproven.

Electroacupuncture Ineffective for Neuropathy
Posted by SB. Leavitt, MA, PhD Thursday, September 22, 2011

A recently reported clinical trial examined electroacupuncture — needles inserted at acupoints with electric current applied — for chronic, peripheral neuropathic pain. This therapy afforded no significant pain relief or other benefits; however, the study also serves as an example of poor-quality evidence garnering more attention in a pain journal than it probably deserves.

Writing online ahead of publication in the journal Pain Medicine, researchers in Milan, Italy, report a double-blind, placebo-controlled, cross-over trial to investigate the analgesic efficacy of electroacupuncture (EA) in patients with axonal polyneuropathy [Penza et al. 2011]. They included 16 patients with a diagnosis of chronic neuropathic pain in their lower limbs — Visual Analog Scale [VAS] score > 4.0 for at least 6 months — and taking analgesic medications for at least 3 months at stable doses. There were 9 females and 7 males enrolled; mean age 64.9 years (range 43-75 years).

Subjects were randomized into either EA or Sham-EA (placebo) groups and treated weekly. The protocol involved 6 weeks of treatment, 12 weeks free of treatment, and then cross-over to the alternate group for a further 6 weeks of treatment. Therefore, by the end of 24 weeks all patients had received both EA and Sham-EA, making a total of 16 subjects per group. The primary outcome measure was the number of patients treated with EA achieving at least a 50% improvement from baseline in pain relief, as compared with placebo. Secondary outcomes were improvements in patients’ global impressions of change, depression and anxiety, and quality of life.

Results indicated that only one (1) patient in each group (EA and Sham-EA) reported 50% pain relief at the end of treatment compared with their pain intensity at baseline. Changes in pain intensity were not statistically significant and did not substantially differ between EA (Mean ± SD on VAS: 5.7 ± 2.3 at baseline and 4.97 ± 3.23 after treatment) and Sham-EA (4.9 ± 1.9 at baseline and 4.18 ± 2.69 after treatment). There also were no changes in the secondary outcomes; however, no adverse effects of therapy were recorded for either group.

The authors conclude that their results do not support the use of EA in this population of patients with painful neuropathy, and further trials in larger groups of patients are warranted to confirm this observation. However, this study may not justify any conclusion regarding EA one way or the other.

COMMENTARY: Acupuncture is an ancient modality that is a somewhat popular complementary or alternative therapy for the management of select pain conditions; however, it also is controversial. In some circles, there is considerable skepticism as to whether acupuncture is a science, a pseudoscience, or a hoax [eg, see SBM blogpost here].

The term acupuncture pertains to procedures that stimulate precise anatomical locations by various techniques to produce clinical effects. Besides techniques described in Traditional Chinese Medicine (TCM), variations now include Nogier auricular (ear) acupuncture, Koryo hand acupuncture, Yamamoto scalp acupuncture, and Po abdominal acupuncture. Acupuncture points can be stimulated by surface pressure (acupressure), insertion of needles without manipulation, insertion of needles with manipulation (twisting and/or thrusting), heating of acupuncture needles through radiant heat or moxibustion, laser stimulation of acupuncture points, and electrical stimulation of inserted needles, or electroacupuncture, as in the study by Penza et al. described above.

In a review last April 2011, a practitioner from the Mayo Clinic wrote quite favorably of acupuncture as potentially benefitting a diversity of chronic pain conditions [Dorsher 2011]. At about that same time, Ernst and colleagues reported an overview of 57 qualifying reviews — published between 2000 and 2009, incorporating nearly 700 trials — and concluded there is little convincing evidence that acupuncture is effective in reducing many types of pain and there also should be concerns about its safety [see UPDATE here]. In other Pain-Topics UPDATES [eg, here, here, and here], we have commented on conflicting, and sometimes confusing, evidence of acupuncture’s efficacy.

This present study by Penza and colleagues does little, if anything, to clarify the uncertainties surrounding acupuncture or, in particular, electroacupuncture. For example…
Relatively few data are included for interpretation in the article, overall, and the authors do not report having conducted a power analysis to justify the small number of subjects enrolled. Our own calculation finds that, at 80% power and with relatively small standard deviations (ie, high precision) a total of 16 subjects per group could be sufficient to demonstrate a statistically significant large effect size greater than 1.0 (50% absolute reduction in pain) if it does exist. However, the design is weakened by the cross-over design — in effect having each subject serve as their own placebo control — and such small numbers of subjects would not have external validity even if a very large effect size as a result of active EA were demonstrated [see UPDATE discussing statistical power here].

Note: In fairness, the authors do report checking for a cross-over interaction, and found there was no difference in VAS scores between patients who received EA as their first treatment and patients initially treated with placebo. But, again, with so few subjects in these analyses it is difficult to know if the statistics can be trusted as being valid or relevant for a larger population.

Mean baseline VAS scores in the two groups (EA=5.7, Sham-EA=4.9), suggest that these were patients with only moderate neuropathic pain at the outset and large reductions in pain could be more difficult to achieve than in patients having severe pain [see UPDATE here]. So, hypothesizing a possible 50% reduction in VAS scores as a result of EA, and with such a small number of subjects having only moderate pain to demonstrate this, might have been unrealistic and “stacked the deck” so to speak against a significantly successful outcome.

It seems unusual that there was such a diminutive response to active EA and that even a typical placebo response to Sham-EA also was suppressed. Responsiveness to both active treatment and placebo might have been confounded by the unspecified analgesics that patients were taking pretrial and were asked to continue throughout the study.

Furthermore, throughout the research literature on acupuncture, questions have been raised about the validity of sham or placebo approaches, and this study is no exception. The researchers report that “pseudo” or Sham-EA was performed by applying needles in neutral anatomical points, close to true acupoints, and delivering the same electrical stimulation as in the active EA condition; that is, alternating electric current at low voltage (6 mV) and low frequency (2-10 Hz). In some research, even minimal needling of skin over acupuncture and non-acupuncture point locations has produced physiological effects that muddle differences between placebo responses and therapeutic efficacy. And, the subcutaneous administration of electrical current at any location might possibly affect nerve transmission to alter neuropathic pain perception.

Therefore, the mere act of inserting needles, the positioning of the needles, and the application of electrical currents at the specified voltage/frequency may have been confounding factors that combined to cancel-out rather than facilitate responses to either active or placebo therapy. Or, electroacupuncture may simply be a largely inert and ineffective therapy for neuropathic pain — we do not really have any definitive answers from this trial, nor is there a solid direction for designing larger, confirmatory trials.

Probably the most puzzling aspect of this low-quality study is why it was published in the (supposedly) peer-reviewed journal Pain Medicine from the American Academy of Pain Medicine. It only narrowly qualifies as a pilot study and barely has adequate substance to be a non-juried poster presentation at a pain conference; so, why is it published as a 5-page journal article?! Studies of this low caliber being published in pain journals is becoming overly common these days and, of further concern, the article now will be indexed in Medline and similar services, cited by other authors as scientific “proof” against electroacupuncture, and included in future data meta-analyses on the subject.

While we have consistently neither endorsed nor eschewed acupuncture, or any of its variations, studies such as this do nothing to help confirm or deny the validity of acupuncture as a modality for better pain management. The field deserves, and reputable journals should insist upon, much better research.

REFERENCES:
> Dorsher PT. Acupuncture for chronic pain. Tech Regional Anesth Pain Managmt. 2011(April);15(2):55-63 [abstract here].
> Penza P, Bricchi M, Scola A, et al. Electroacupuncture Is Not Effective in Chronic Painful Neuropathies. Pain Medicine. 2011(Sep 14), published online ahead of print [abstract here].

http://updates.pain-topics.org/2011/09/electroacupuncture-ineffective-for.html